AstraZeneca COVID drug Evusheld approved in Israel for people with weakened immune systems
The drug has been shown to reduce severe morbidity and mortality from Covid by 83 percent, it added.
Jerusalem: The Israeli Ministry of Health has approved the administration of AstraZeneca's Evusheld Covid-19 drug to people with weakened immune systems. The antibody drug, which includes two injections of two types of long-acting antibodies given at the same time, is only authorised for those who are not currently infected or have not recently been exposed to an individual infected with...
Jerusalem: The Israeli Ministry of Health has approved the administration of AstraZeneca's Evusheld Covid-19 drug to people with weakened immune systems.
The antibody drug, which includes two injections of two types of long-acting antibodies given at the same time, is only authorised for those who are not currently infected or have not recently been exposed to an individual infected with the virus, Xinhua news agency reported.
The antibodies bind to the spike protein of the virus and neutralise the entry of the virus into the human cells, thus reducing the risk of developing a symptomatic disease, the ministry noted on Tuesday.
Evusheld, formerly known as AZD7442, is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.
The drug has been shown to reduce severe morbidity and mortality from Covid by 83 per cent, it added.
Read also: AstraZeneca in touch with Indian authorities for COVID drug Evusheld
The ministry approved the treatment for those aged 12 and above, weighing at least 40 kgs, with moderate to severely compromised immune systems.
In early December 2021, the treatment received an emergency use authorisation by the US Food and Drug Administration (FDA) in certain adults and pediatric individuals with weakened immune systems or with a history of severe adverse reactions to a Covid vaccine.
Read also: AstraZeneca COVID antibody combination to be manufactured by Samsung Biologics
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Read also: AstraZeneca antibody cocktail Evusheld works against Omicron: USFDA study
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd